It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany)
to discuss the results from the maintenance phase of the True North study, investigating corticosteroid free remission in patients with ulcerative colitis treated with ozanimod.
The abstract entitled ‘142: CORTICOSTEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD: RESULTS FROM THE MAINTENANCE PHASE OF TRUE NORTH’ was presented at DDW 2021, May 21-23.
- Could you give us a brief overview of the True North study and its findings? (0:11)
- Why is corticosteroid-free remission an important treatment goal in ulcerative colitis? (1:40)
- How were corticosteroid doses tapered in the maintenance phase of the True North study? (2:25)
- What were the results of the maintenance phase in terms of corticosteroid-free remission? (3:07)
- What are the implications of this finding, both for clinical practice and for future clinical trial design? (3:34)
Disclosures: Stefan Schreiber reports personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist, and Falk, outside the submitted DDW work.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of DDW 2021 (Virtual).
Share this Video
Related Videos In Inflammatory Bowel Disease
Stefan Schreiber, ECCO 2021: Risankizumab – an Induction Therapy for Crohn’s Disease
We were delighted to catch up with Professor Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, Germany) to discuss the results from the phase 3 ADVANCE and MOTIVATE studies, investigating risankizumab as an induction therapy in patients with moderate-to-severe Crohn’s Disease. The abstract ‘Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results […]
Stefan Schreiber, ECCO 2021: Filgotinib for the Treatment of Ulcerative Colitis
TouchIMMUNOLOGY had the pleasure of talking to Professor Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, Germany) around the efficacy and safety findings from the SELECTION study and its long term extension. The abstract ‘Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension study.‘ (OP04) was […]
Eamonn Quigley, DDW 2021: Biotherapeutic Blautia Hydrogentrophica in IBS
It was a pleasure to speak with Prof. Eamonn Quigley (Houston Methodist Hospital, Houston, TX, USA) about the phase 2 study of the single-strain live biotherapeutic, Blautia hydrogentrophica (Blautix), currently under investigation in irritable bowel syndrome (IBS). His abstract entitled ‘A Phase 2 Study of Live Biotherapeutic Blautix in Irritable Bowel Syndrome (IBS) Patients with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!